BRIEF

on SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma Opens State-of-the-Art Production Facility in Hungary

SCHOTT Pharma AG & Co. KGaA has inaugurated a new production facility for prefillable glass syringes in Lukácsháza, Hungary. The facility was completed after an investment of EUR 76 million and 1.5 years of construction. This expansion is set to support growing trends in the pharmaceutical market, particularly in the demand for specialty glass syringes.

The Hungarian government contributed EUR 9 million to the project, which will create over 120 new jobs in the region. This new facility is part of SCHOTT Pharma's strategy to increase its global capacities and enhance its competitiveness in Europe. The company plans to invest further millions in Hungary to keep up with the dynamic market.

SCHOTT Pharma's CEO, Andreas Reisse, emphasized the significance of prefillable glass syringes for various medications, including critical vaccines and innovative biologics. These syringes provide long-term storage solutions and improve medication administration accuracy, benefiting both healthcare professionals and patients.

The new facility strengthens SCHOTT Pharma's existing operations in Hungary, already a key supplier of drug containment systems to the global market. Equipped with advanced machinery, it mirrors the high-end processes and quality assurance standards of SCHOTT Pharma's global network.

More details on SCHOTT Pharma's prefillable glass syringes can be found on their official website.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SCHOTT Pharma AG & Co. KGaA news